Portal de Periódicos da CAPES

Incidence, clinical, risk factors and outcomes of Guillain‐Barré in Covid‐19

2020; Wiley; Volume: 89; Issue: 3 Linguagem: Inglês

10.1002/ana.25987

1531-8249

Marcos Fragiel, Òscar Miró, Pere Llorens, Sònia Jiménez, Pascual Piñera, Guillermo Burillo, Alfonso Martı́n, Francisco Javier Martín‐Sánchez, Eric Jorge García‐Lamberechts, Javier Jacob, Aitor Alquézar‐Arbé, Ricardo Juárez, Blas Jiménez, Rigoberto del Río, Miriam Mateo Roca, Arturo Huerta, Nieves López-Laguna, María Pilar López Díez, Jorge Pedraza García, Amparo Fernández de Simón Almela, Juan José López Díaz, Patricia Eiroa Hernández, Noemí Ruiz de Lobera, J. Porta‐Etessam, Cristina Fernández, Elpidio Calvo, Juan González del Castillo,

Retinal and Optic Conditions

We diagnosed 11 Guillain–Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2‐month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non‐COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18–12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant‐years, respectively, OR = 13.5, 95% CI = 9.87–18.4). Regarding clinical characteristics, olfactory–gustatory disorders were more frequent in COVID‐GBS than non‐COVID–GBS (OR = 27.59, 95% CI = 1.296–587) and COVID–non‐GBS (OR = 7.875, 95% CI = 1.587–39.09) patients. Although COVID‐GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS‐CoV‐2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598–603